These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29931312)

  • 1. Circulating Tumor DNA Assays in Clinical Cancer Research.
    Ossandon MR; Agrawal L; Bernhard EJ; Conley BA; Dey SM; Divi RL; Guan P; Lively TG; McKee TC; Sorg BS; Tricoli JV
    J Natl Cancer Inst; 2018 Sep; 110(9):929-934. PubMed ID: 29931312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
    Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
    J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technical considerations for circulating tumor DNA detection in oncology.
    Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
    Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working Group.
    Godsey JH; Silvestro A; Barrett JC; Bramlett K; Chudova D; Deras I; Dickey J; Hicks J; Johann DJ; Leary R; Lee JSH; McMullen J; McShane L; Nakamura K; Richardson AO; Ryder M; Simmons J; Tanzella K; Yee L; Leiman LC
    Clin Chem; 2020 Sep; 66(9):1156-1166. PubMed ID: 32870995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cornerstone of integrating circulating tumor DNA into cancer management.
    Li Z; Yi L; Gao P; Zhang R; Li J
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):1-11. PubMed ID: 30419316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
    El Achi H; Khoury JD; Loghavi S
    Curr Hematol Malig Rep; 2019 Oct; 14(5):358-367. PubMed ID: 31346903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
    Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
    Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
    Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
    J Clin Oncol; 2018 Jun; 36(16):1631-1641. PubMed ID: 29504847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.
    Fettke H; Steen JA; Kwan EM; Bukczynska P; Keerthikumar S; Goode D; Docanto M; Ng N; Martelotto L; Hauser C; Southey MC; Azad AA; Nguyen-Dumont T
    Biotechniques; 2020 Aug; 69(2):133-140. PubMed ID: 32654508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Introduction and Clinical Application of Cell-Free Tumor DNA.
    Li J; Liu R; Huang C; Chen S; Xu M
    Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
    Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
    Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.